ANIK vs. OSUR, CERS, UTMD, ATRI, SRDX, PLSE, SKIN, NPCE, TCMD, and BVS
Should you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include OraSure Technologies (OSUR), Cerus (CERS), Utah Medical Products (UTMD), Atrion (ATRI), Surmodics (SRDX), Pulse Biosciences (PLSE), Beauty Health (SKIN), NeuroPace (NPCE), Tactile Systems Technology (TCMD), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
Anika Therapeutics presently has a consensus target price of $29.50, suggesting a potential upside of 15.37%. OraSure Technologies has a consensus target price of $6.38, suggesting a potential upside of 19.83%. Given OraSure Technologies' higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Anika Therapeutics.
91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 5.9% of Anika Therapeutics shares are owned by company insiders. Comparatively, 3.4% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
OraSure Technologies has a net margin of 13.23% compared to Anika Therapeutics' net margin of -49.60%. OraSure Technologies' return on equity of 14.50% beat Anika Therapeutics' return on equity.
OraSure Technologies received 248 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 69.86% of users gave OraSure Technologies an outperform vote while only 64.30% of users gave Anika Therapeutics an outperform vote.
Anika Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.
In the previous week, OraSure Technologies had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for OraSure Technologies and 3 mentions for Anika Therapeutics. OraSure Technologies' average media sentiment score of 0.01 beat Anika Therapeutics' score of -0.26 indicating that OraSure Technologies is being referred to more favorably in the news media.
OraSure Technologies has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
OraSure Technologies beats Anika Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Anika Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anika Therapeutics Competitors List
Related Companies and Tools
